AstraZeneca/$AZN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Ticker

$AZN
Primary listing

Industry

Pharmaceuticals

Employees

94,300

ISIN

US0463531089

AstraZeneca Metrics

BasicAdvanced
$217B
14.06
$4.97
0.18
$1.52
2.95%

What the Analysts think about AstraZeneca

Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.

Bulls say / Bears say

AstraZeneca reported a 10% year-on-year increase in revenue to $13.6 billion in Q1 2025, driven by strong sales in cancer drugs and biopharmaceuticals. (ft.com)
The company is investing $2.5 billion in a new research center in Beijing, reflecting its commitment to the Chinese market despite recent challenges. (fastbull.com)
Analysts maintain a 'Buy' rating on AstraZeneca, with price targets up to $99, indicating confidence in the company's growth prospects. (markets.businessinsider.com)
AstraZeneca faces a US class action lawsuit alleging misleading statements about regulatory investigations in China, which could impact investor confidence. (ft.com)
The detention of AstraZeneca's top executive in China and ongoing regulatory probes pose significant operational risks in a key market. (reuters.com)
Potential US tariffs on pharmaceutical products from the EU could affect AstraZeneca's financial performance if implemented. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2025.

AstraZeneca Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AstraZeneca Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AZN

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs